iBio, Inc. (IBIO) NASDAQ
1.70
+0.2(+13.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.70
+0.2(+13.33%)
Currency In USD
| Previous Close | 1.5 |
| Open | 1.52 |
| Day High | 1.74 |
| Day Low | 1.51 |
| 52-Week High | 3.82 |
| 52-Week Low | 0.56 |
| Volume | 729,451 |
| Average Volume | 1.02M |
| Market Cap | 26.84M |
| PE | -3.04 |
| EPS | -0.56 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 1.61 |
| Change | 0.2 |
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie dietSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapi
iBio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran,
iBio Announces $26 Million Private Placement
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality i